Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ocugen, Inc.OCGN · Entity 5550 | Senior Vice President | May 04, 2021 | May 06, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ocugen, Inc.
Report date May 04, 2021 · Filed May 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-05-04 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2021-05-04 · Exercise / conversion · Acquired 4,900 · Balance 4,900 Row 2 · 2021-05-04 · Sale · Disposed 4,900 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Row 3 · 2021-05-04 · Exercise / conversion · Acquired 2,000 · Balance 2,000 Row 4 · 2021-05-04 · Sale · Disposed 2,000 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Row 5 · 2021-05-04 · Exercise / conversion · Acquired 6,500 · Balance 6,500 Row 6 · 2021-05-04 · Sale · Disposed 6,500 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.35 to $13.71. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 7 · 2021-05-04 · Exercise / conversion · Acquired 2,311 · Balance 2,311 Row 8 · 2021-05-04 · Sale · Disposed 2,311 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.46 · Expires 2024-09-18 | Direct | 0 |
Reported balance
After 2021-05-04 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-05-04 · Exercise / conversion · Disposed 4,900 · Balance 0 F3: All of the options became exerciable immediately upon grant. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.94 · Expires 2026-04-26 | Direct | 2,191 |
Reported balance
After 2021-05-04 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-05-04 · Exercise / conversion · Disposed 2,000 · Balance 2,191 F3: All of the options became exerciable immediately upon grant. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.51 · Expires 2030-01-02 | Direct | 58,261 |
Reported balance
After 2021-05-04 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-05-04 · Exercise / conversion · Disposed 6,500 · Balance 58,261 F4: The option, initially representing a right to purchase a total of 77,641 shares, vests and becomes exercisable annually in equal installments over three years commencing on January 2, 2021, subject to continued service with the Company on the applicable vesting dates. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.57 · Expires 2030-08-14 | Direct | 42,578 |
Reported balance
After 2021-05-04 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-05-04 · Exercise / conversion · Disposed 2,311 · Balance 42,578 F5: The option, initially representing a right to purchase a total of 50,000 shares, vests and becomes exercisable in equal monthly installments over three years commencing on September 14, 2020, subject to continued service with the Company on the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.35 to $13.71. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: All of the options became exerciable immediately upon grant.
F4: The option, initially representing a right to purchase a total of 77,641 shares, vests and becomes exercisable annually in equal installments over three years commencing on January 2, 2021, subject to continued service with the Company on the applicable vesting dates.
F5: The option, initially representing a right to purchase a total of 50,000 shares, vests and becomes exercisable in equal monthly installments over three years commencing on September 14, 2020, subject to continued service with the Company on the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2021 Filed May 6, 2021 00:15 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOptions (Right to Buy) · Derivative | 2,311 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001192482-21-000405 · edgar.xml · derivative · entry 12 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,578 Underlying: Common Stock · 2,311 shares Expires 2030-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, initially representing a right to purchase a total of 50,000 shares, vests and becomes exercisable in equal monthly installments over three years commencing on September 14, 2020, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| May 04, 2021 Filed May 6, 2021 00:15 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOptions (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001192482-21-000405 · edgar.xml · derivative · entry 11 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,261 Underlying: Common Stock · 6,500 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, initially representing a right to purchase a total of 77,641 shares, vests and becomes exercisable annually in equal installments over three years commencing on January 2, 2021, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| May 04, 2021 Filed May 6, 2021 00:15 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOptions (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001192482-21-000405 · edgar.xml · derivative · entry 10 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,191 Underlying: Common Stock · 2,000 shares Expires 2026-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the options became exerciable immediately upon grant. Read SEC document |
| May 04, 2021 Filed May 6, 2021 00:15 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOptions (Right to Buy) · Derivative | 4,900 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001192482-21-000405 · edgar.xml · derivative · entry 9 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,900 shares Expires 2024-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the options became exerciable immediately upon grant. Read SEC document |
| May 04, 2021 Filed May 6, 2021 00:15 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 2,311 | $13.81 | $31,914.91 |
DisclosureSEC source: 0001192482-21-000405 · edgar.xml · nonDerivative · entry 8 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 04, 2021 Filed May 6, 2021 00:15 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 2,311 | $0.57 | $1,305.72 |
DisclosureSEC source: 0001192482-21-000405 · edgar.xml · nonDerivative · entry 7 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2021 Filed May 6, 2021 00:15 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 6,500 | $13.50 | $87,750.00 |
DisclosureSEC source: 0001192482-21-000405 · edgar.xml · nonDerivative · entry 6 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.35 to $13.71. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 04, 2021 Filed May 6, 2021 00:15 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 6,500 | $0.51 | $3,315.00 |
DisclosureSEC source: 0001192482-21-000405 · edgar.xml · nonDerivative · entry 5 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2021 Filed May 6, 2021 00:15 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 2,000 | $13.81 | $27,620.00 |
DisclosureSEC source: 0001192482-21-000405 · edgar.xml · nonDerivative · entry 4 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 04, 2021 Filed May 6, 2021 00:15 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 2,000 | $2.94 | $5,880.00 |
DisclosureSEC source: 0001192482-21-000405 · edgar.xml · nonDerivative · entry 3 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2021 Filed May 6, 2021 00:15 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 4,900 | $13.81 | $67,669.00 |
DisclosureSEC source: 0001192482-21-000405 · edgar.xml · nonDerivative · entry 2 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 04, 2021 Filed May 6, 2021 00:15 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 4,900 | $0.46 | $2,254.00 |
DisclosureSEC source: 0001192482-21-000405 · edgar.xml · nonDerivative · entry 1 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2021 Filed May 4, 2021 00:53 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOptions (Right to Buy) · Derivative | 4,317 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001192482-21-000388 · edgar.xml · derivative · entry 15 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,900 Underlying: Common Stock · 4,317 shares Expires 2024-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All of the options became exerciable immediately upon grant. Read SEC document |
| May 03, 2021 Filed May 4, 2021 00:53 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 4,317 | $16.00 | $69,072.00 |
DisclosureSEC source: 0001192482-21-000388 · edgar.xml · nonDerivative · entry 10 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 03, 2021 Filed May 4, 2021 00:53 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 4,317 | $0.46 | $1,985.82 |
DisclosureSEC source: 0001192482-21-000388 · edgar.xml · nonDerivative · entry 9 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2021 Filed May 4, 2021 00:53 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOptions (Right to Buy) · Derivative | 5,111 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001192482-21-000388 · edgar.xml · derivative · entry 14 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,889 Underlying: Common Stock · 5,111 shares Expires 2030-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 111,111 shares under the option are exercisable. The option, initially representing a right to purchase a total of 50,000 shares, vests and becomes exercisable over three years commencing on August 14, 2020, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| April 29, 2021 Filed May 4, 2021 00:53 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOptions (Right to Buy) · Derivative | 12,880 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001192482-21-000388 · edgar.xml · derivative · entry 13 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,761 Underlying: Common Stock · 12,880 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 34,507 shares under the option are exercisable. The option, initially representing a right to purchase a total of 77,641 shares, vests and becomes exercisable over three years commencing on January 2, 2021, subject to continued service with the Company on the applicable vesting dates. Read SEC document |
| April 29, 2021 Filed May 4, 2021 00:53 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOptions (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001192482-21-000388 · edgar.xml · derivative · entry 12 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,191 Underlying: Common Stock · 3,000 shares Expires 2026-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All of the options became exerciable immediately upon grant. Read SEC document |
| April 29, 2021 Filed May 4, 2021 00:53 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionOptions (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001192482-21-000388 · edgar.xml · derivative · entry 11 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,217 Underlying: Common Stock · 9,000 shares Expires 2024-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All of the options became exerciable immediately upon grant. Read SEC document |
| April 29, 2021 Filed May 4, 2021 00:53 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 5,111 | $10.96 | $56,016.56 |
DisclosureSEC source: 0001192482-21-000388 · edgar.xml · nonDerivative · entry 8 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.86 to $11.07. Read SEC document |
| April 29, 2021 Filed May 4, 2021 00:53 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 5,111 | $0.57 | $2,913.27 |
DisclosureSEC source: 0001192482-21-000388 · edgar.xml · nonDerivative · entry 7 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2021 Filed May 4, 2021 00:53 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 12,880 | $10.96 | $141,164.80 |
DisclosureSEC source: 0001192482-21-000388 · edgar.xml · nonDerivative · entry 6 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.86 to $11.07. Read SEC document |
| April 29, 2021 Filed May 4, 2021 00:53 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 12,880 | $0.51 | $6,568.80 |
DisclosureSEC source: 0001192482-21-000388 · edgar.xml · nonDerivative · entry 5 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2021 Filed May 4, 2021 00:53 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 3,000 | $10.99 | $32,970.00 |
DisclosureSEC source: 0001192482-21-000388 · edgar.xml · nonDerivative · entry 4 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 29, 2021 Filed May 4, 2021 00:53 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionCommon Stock | 3,000 | $2.94 | $8,820.00 |
DisclosureSEC source: 0001192482-21-000388 · edgar.xml · nonDerivative · entry 3 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2021 Filed May 4, 2021 00:53 UTC | Ocugen, Inc. OCGN · Entity 5550 | SaleCommon Stock | 9,000 | $10.97 | $98,730.00 |
DisclosureSEC source: 0001192482-21-000388 · edgar.xml · nonDerivative · entry 2 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.86 to $11.06. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes (2) - (4) to this Form 4. Read SEC document |
| April 29, 2021 Filed May 4, 2021 00:53 UTC | Ocugen, Inc. OCGN · Entity 5550 | Exercise / conversionComm Stock | 9,000 | $0.46 | $4,140.00 |
DisclosureSEC source: 0001192482-21-000388 · edgar.xml · nonDerivative · entry 1 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 01, 2021 Filed Jan 4, 2021 22:50 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOption (Right to Buy) · Derivative | 220,500 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0001192482-21-000025 · edgar.xml · derivative · entry 1 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,500 Underlying: Common Stock · 220,500 shares Expires 2031-01-01 F1 · derivative.exercise_date: The option vests annually in equal installments over three years commencing on January 1, 2022, subject to continued employment with the Company on the applicable vesting dates. Read SEC document |
| August 14, 2020 Filed Aug 17, 2020 23:55 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOptions (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001192482-20-000676 · edgar.xml · derivative · entry 1 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-08-14 F1 · derivative.exercise_date: The options will vest in equal monthly installments over three years commencing on August 14, 2020, subject to continued employment with the Company on the applicable vesting dates. Read SEC document |
| May 05, 2020 Filed May 7, 2020 23:44 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOptions (Right to Buy) · Derivative | 20,573 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001192482-20-000321 · edgar.xml · derivative · entry 1 Tammara Vijay · CIK 0001791822 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,573 Underlying: Common Stock · 20,573 shares Expires 2030-05-05 F1 · derivative.exercise_date: The options will vest annually in equal installments over three years commencing on May 5, 2021, subject to continued employment with the Company on the applicable vesting dates. Read SEC document |
| January 02, 2020 Filed Jan 4, 2020 01:39 UTC | Ocugen, Inc. OCGN · Entity 5550 | GrantOptions (Right to Buy) · Derivative | 77,641 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001192482-20-000024 · edgar.xml · derivative · entry 1 Tammara Vijay · CIK 0001791822 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,641 Underlying: Common Stock · 77,641 shares Expires 2030-01-02 F1 · derivative.exercise_date: The options will vest annually in equal installments over three years commencing on January 2, 2021, subject to continued employment with the Company on the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.